A Phase 1 interventional study of BMS-985521 and Placebo in Healthy Volunteers, sponsored by Bristol-Myers Squibb. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-07.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the safety, tolerability, and drug levels of BMS-986521 following single and multiple ascending doses of BMS-986521 in healthy adult participants, and to evaluate potential food effects on BMS-986521 exposure.
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BMS-985521 · Other: Placebo
Drug: BMS-985521 · Other: Placebo
Drug: BMS-985521 · Other: Placebo
Drug: BMS-985521 · Other: Placebo
Drug: BMS-985521 · Other: Placebo
Drug: BMS-985521 · Other: Placebo
Drug: BMS-985521 · Other: Placebo
Drug: BMS-985521 · Other: Placebo
Drug: BMS-985521 · Other: Placebo
Drug: BMS-985521 · Other: Placebo
Drug: BMS-985521 · Other: Placebo
Drug: BMS-985521
Specified dose on specified days.
Specified dose on specified days
Number of participants with treatment-emergent adverse events (AEs)
Time frame: Up to approximately Day 40
Number of participants with treatment-emergent serious adverse events (SAEs)
Time frame: Up to approximately Day 40
Number of participants with Treatment-emergent suicidal ideation and behavior as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
Time frame: Up to approximately Day 14
Maximum Concentration (Cmax) of BMS-986521 in Plasma
Time frame: Up to approximately Day 14
Time to Cmax (Tmax) of BMS-986521 in Plasma
Time frame: Up to approximately Day 14
Area Under the Concentration-Time Curve from Time Zero to the Last Measured Time Point (AUC(0-T)) of BMS-986521 in Plasma
Time frame: Up to approximately Day 14
Area Under the Concentration-Time Curve from Time Zero to 24 Hours (AUC(0-24)) of BMS-986521 in Plasma
Time frame: Up to approximately Day 14
Area Under the Concentration-Time Curve from Time Zero Extrapolated to Infinity (AUC(INF)) of BMS-986521 in Plasma
Time frame: Up to approximately Day 14
Concentration Over a Dosing Interval (tau) (AUC(TAU)) of BMS-986521 in Plasma
Time frame: Up to approximately Day 14
Elimination Half-Life (T-HALF) of BMS-986521 in Plasma
Time frame: Up to approximately Day 14
Apparent Clearance of BMS-986521 from Plasma after Dosing (CLT/F)
Time frame: Up to approximately Day 14
Apparent Volume of Distribution in Plasma after Dosing (Vz/F) of BMS-986521
Time frame: Up to approximately Day 14
Accumulation Index Based on Maximum Concentration (Cmax) in Plasma after Multiple Dosing (AI_Cmax) of BMS-986521
Time frame: Up to approximately Day 14
Accumulation Index Based on Area Under the Curve (AUC) in Plasma After Multiple Dosing (AI_AUC) of BMS-986521
Time frame: Up to approximately Day 14
Geometric Mean Cmax BMS-986521 under fed and fasted conditions
Cohort 3
Time frame: Up to approximately Day 11
Geometric Mean AUC(0-T) BMS-986521 under fed and fasted conditions
Cohort 3
Time frame: Up to approximately Day 11
Geometric Mean AUC(INF) BMS-986521 under fed and fasted conditions
Cohort 3
Time frame: Up to approximately Day 11
Geometric mean ratios of Cmax for BMS-986521 oral tablet vs solution
Part C
Time frame: Up to approximately Day 11
Geometric mean ratios of AUC(0-T) for BMS-986521 oral tablet vs solution
Part C
Time frame: Up to approximately Day 11
Geometric mean ratios of AUC(INF) for BMS-986521 oral tablet vs solution
Part C
Time frame: Up to approximately Day 11
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Started Dec 2025 (actual). Primary completion is estimated for Nov 2026, 10 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.